By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Drugs > Entrectinib (systemic) (monograph) > Entrectinib Dosage
Drugs
https://themeditary.com/dosage-information/entrectinib-dosage-15606.html

Entrectinib Dosage

Drug Detail:Entrectinib (systemic) (monograph) (Rozlytrek)

Drug Class:

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Non-Small Cell Lung Cancer

600 mg orally once a day until disease progression or unacceptable toxicity

Use: For adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive

Usual Adult Dose for Solid Tumors

600 mg orally once a day until disease progression or unacceptable toxicity

Uses: For adult patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity; and have progressed following treatment or have no satisfactory alternative therapy.

Usual Pediatric Dose for Solid Tumors

12 years and older:

  • Body surface area (BSA) greater than 1.5 m2: 600 mg orally once a day
  • BSA 1.11 to 1.5 m2: 500 mg orally once a day
  • BSA 0.91 to 1.1 m2: 400 mg orally once a day

Use: For pediatric patients 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity; and have progressed following treatment or have no satisfactory alternative therapy.

Renal Dose Adjustments

  • Mild or moderate renal impairment (CrCl 30 to less than 90 mL/min: No adjustment recommended.
  • Severe renal impairment (CrCl greater than 30 mL/min): Data not available

Liver Dose Adjustments

  • Grade 3 hepatic impairment: Withhold therapy until recovery to less than or equal to Grade 1 or baseline; resume at same dose if resolution occurs within 4 weeks; permanently discontinue if adverse reaction does not resolve within 4 weeks; resume at reduced dose for recurrent Grade 3 events that resolve within 4 weeks.
  • Grade 4 hepatic impairment: Withhold therapy until recovery to less than or equal to Grade 1 or baseline; resume at reduced dose if resolution occurs within 4 weeks; permanently discontinue if adverse reaction does not resolve within 4 weeks; permanently discontinue for recurrent Grade 4 events.
  • ALT or AST greater than 3 times upper limit of normal (ULN) with concurrent total bilirubin greater than 1.5 x ULN (in the absence of cholestasis or hemolysis): Permanently discontinue therapy.

Dose Adjustments

DOSE REDUCTIONS FOR ADVERSE REACTIONS:
FIRST DOSE REDUCTION:

  • Adults and pediatric patients 12 years and older with BSA greater than 1.50 m2: 400 mg orally once daily
  • Pediatric patients 12 years and older with BSA of 1.11 to 1.50 m2: 400 mg orally once daily
  • Pediatric patients 12 years and older with BSA of 0.91 to 1.1 m2: 300 mg orally once daily
SECOND DOSE REDUCTION (if the patient cannot tolerate the second dose reduction permanently discontinue therapy):
  • Adults and pediatric patients 12 years and older with BSA greater than 1.50 m2: 200 mg orally once daily
  • Pediatric patients 12 years and older with BSA of 1.11 to 1.50 m2: 200 mg orally once daily
  • Pediatric patients 12 years and older with BSA of 0.91 to 1.1 m2: 200 mg orally once daily

DOSE MODIFICATIONS FOR ADVERSE REACTIONS:
CONGESTIVE HEART FAILURE:
  • Grade 2 or 3: Withhold therapy until recovered to less than or equal to Grade 1; resume at reduced dose.
  • Grade 4: Permanently discontinue therapy.
CENTRAL NERVOUS SYSTEM EFFECTS:
  • Intolerable Grade 2: Withhold therapy until recovered to less than or equal to Grade 1 or baseline; resume at same dose or reduced dose.
  • Grade 3: Withhold therapy until recovered to less than or equal to Grade 1 or baseline; resume at same dose if resolution occurs within 4 weeks; permanently discontinue if adverse reaction does not resolve within 4 weeks; resume at a reduced dose for recurrent Grade 3 events that resolve within 4 weeks.
  • Grade 4: Withhold therapy until recovered to less than or equal to Grade 1 or baseline; resume at same dose or reduced dose if resolution occurs within 4 weeks; permanently discontinue if adverse reaction does not resolve within 4 weeks; permanently discontinue therapy for recurrent Grade 4 events.
HYPERURICEMIA:
  • QTc greater than 500 ms: Withhold therapy until QTc interval recovers to baseline; resume at same dose if factors that cause QT prolongation are identified and corrected; resume at reduced dose if other factors that cause QT prolongation are not identified.
  • Torsade de pointes; polymorphic ventricular tachycardia; signs/symptoms of serious arrhythmia: Permanently discontinue therapy.
VISION DISORDERS:
  • Grade 2 or higher: Withhold therapy until improvement or stabilization; resume at same dose or reduced dose as appropriate.
ANEMIA OR NEUTROPENIA:
  • Grade 3 or 4: Withhold therapy until adverse reaction resolves or improves to recovery or improvement to Grade 1 or baseline; resume at the same or reduced dose, if resolution occurs within 4 weeks; permanently discontinue if adverse reaction does not resolve within 4 weeks; permanently discontinue for recurrent Grade 4 events.

DOSAGE MODIFICATIONS FOR DRUG INTERACTIONS:
MODERATE AND STRONG CYP450 3A INHIBITORS:
Adults and pediatric patients 12 years and older with BSA Greater than 1.5 m2: Avoid coadministration of this drug with moderate or strong CYP450 3A inhibitors; if coadministration cannot be avoided, reduce the dose of this drug as follows:
  • Moderate CYP450 3A Inhibitors: 200 mg orally once daily
  • Strong CYP450 3A Inhibitors: 100 mg orally once daily
After discontinuation of a strong or moderate CYP450 3A inhibitor for 3 to 5 elimination half-lives, resume the dose that was taken prior to initiating the CYP450 3A inhibitor.

Precautions

CONTRAINDICATIONS:

  • None

Safety and efficacy have not been established in patients younger than 12 years with solid tumors who have an NTRK gene fusion have not been established.
Safety and efficacy have not been established in patients younger than 18 years with ROS1-positive NSCLC have not been established.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • This drug may be taken with or without food.
  • Swallow capsules whole do not open, crush, chew, or dissolve the contents of the capsule.
  • If a dose is missed, take it as soon as it is remembered unless the next dose is due within 12 hours.
  • If a patient vomits immediately after taking a dose, instruct them to repeat that dose.

Storage requirements:
  • Store below 30C (86F).

General:
  • Select patients for the treatment of metastatic non-small lung cancer (NSCLC) with this drug based on the presence of ROS1 rearrangement(s) in tumor specimens.
  • Select patients for treatment of locally advanced or metastatic solid tumors with this drug based on the presence of a NTRK gene fusion.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by